These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 15632378)

  • 41. Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.
    Maximov PY; McDaniel RE; Fernandes DJ; Bhatta P; Korostyshevskiy VR; Curpan RF; Jordan VC
    J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25258390
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes.
    Maximov PY; McDaniel RE; Fernandes DJ; Korostyshevskiy VR; Bhatta P; Mürdter TE; Flockhart DA; Jordan VC
    Br J Pharmacol; 2014 Dec; 171(24):5624-35. PubMed ID: 25073551
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.
    Binkhorst L; Mathijssen RH; Jager A; van Gelder T
    Cancer Treat Rev; 2015 Mar; 41(3):289-99. PubMed ID: 25618289
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
    Scordo MG; Spina E; Dahl ML; Gatti G; Perucca E
    Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):296-301. PubMed ID: 16236141
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6.
    Desmarais JE; Looper KJ
    J Clin Psychiatry; 2009 Dec; 70(12):1688-97. PubMed ID: 20141708
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.
    Wegman P; Vainikka L; Stål O; Nordenskjöld B; Skoog L; Rutqvist LE; Wingren S
    Breast Cancer Res; 2005; 7(3):R284-90. PubMed ID: 15987423
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
    Gaston C; Kolesar J
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment.
    Marcath LA; Deal AM; Van Wieren E; Danko W; Walko CM; Ibrahim JG; Weck KE; Jones DR; Desta Z; McLeod HL; Carey LA; Irvin WJ; Hertz DL
    Pharmacogenet Genomics; 2017 Nov; 27(11):402-409. PubMed ID: 28877533
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites.
    Jager NG; Koornstra RH; Vincent AD; van Schaik RH; Huitema AD; Korse TM; Schellens JH; Linn SC; Beijnen JH
    BMC Cancer; 2013 Dec; 13():612. PubMed ID: 24373320
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Applications of CYP450 testing in the clinical setting.
    Samer CF; Lorenzini KI; Rollason V; Daali Y; Desmeules JA
    Mol Diagn Ther; 2013 Jun; 17(3):165-84. PubMed ID: 23588782
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.
    Nowell SA; Ahn J; Rae JM; Scheys JO; Trovato A; Sweeney C; MacLeod SL; Kadlubar FF; Ambrosone CB
    Breast Cancer Res Treat; 2005 Jun; 91(3):249-58. PubMed ID: 15952058
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
    Ratliff B; Dietze EC; Bean GR; Moore C; Wanko S; Seewaldt VL
    J Natl Cancer Inst; 2004 Jun; 96(11):883; author reply 884-5. PubMed ID: 15173275
    [No Abstract]   [Full Text] [Related]  

  • 53. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
    Rae JM; Drury S; Hayes DF; Stearns V; Thibert JN; Haynes BP; Salter J; Sestak I; Cuzick J; Dowsett M;
    J Natl Cancer Inst; 2012 Mar; 104(6):452-60. PubMed ID: 22395643
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine.
    McAlpine DE; Biernacka JM; Mrazek DA; O'Kane DJ; Stevens SR; Langman LJ; Courson VL; Bhagia J; Moyer TP
    Ther Drug Monit; 2011 Feb; 33(1):14-20. PubMed ID: 21099743
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
    de Graan AJ; Teunissen SF; de Vos FY; Loos WJ; van Schaik RH; de Jongh FE; de Vos AI; van Alphen RJ; van der Holt B; Verweij J; Seynaeve C; Beijnen JH; Mathijssen RH
    J Clin Oncol; 2011 Aug; 29(24):3240-6. PubMed ID: 21768449
    [TBL] [Abstract][Full Text] [Related]  

  • 56. How often did Belgian physicians co-prescribe tamoxifen with strong CYP2D6 inhibitors over the last 6 years?
    Dieudonné AS; De Nys K; Casteels M; Wildiers H; Neven P
    Acta Clin Belg; 2014; 69(1):47-52. PubMed ID: 24635399
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.
    Helland T; Henne N; Bifulco E; Naume B; Borgen E; Kristensen VN; Kvaløy JT; Lash TL; Alnæs GIG; van Schaik RH; Janssen EAM; Hustad S; Lien EA; Mellgren G; Søiland H
    Breast Cancer Res; 2017 Nov; 19(1):125. PubMed ID: 29183390
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.
    Thompson AM; Johnson A; Quinlan P; Hillman G; Fontecha M; Bray SE; Purdie CA; Jordan LB; Ferraldeschi R; Latif A; Hadfield KD; Clarke RB; Ashcroft L; Evans DG; Howell A; Nikoloff M; Lawrence J; Newman WG
    Breast Cancer Res Treat; 2011 Jan; 125(1):279-87. PubMed ID: 20809362
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.
    Ahern TP; Hertz DL; Damkier P; Ejlertsen B; Hamilton-Dutoit SJ; Rae JM; Regan MM; Thompson AM; Lash TL; Cronin-Fenton DP
    Am J Epidemiol; 2017 Jan; 185(2):75-85. PubMed ID: 27988492
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer.
    Rangel LB; Taraba JL; Frei CR; Smith L; Rodriguez G; Kuhn JG
    Breast Cancer Res Treat; 2014 Dec; 148(3):571-80. PubMed ID: 25395315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.